,0
zip,02210
sector,Healthcare
fullTimeEmployees,3400
longBusinessSummary,"Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts."
city,Boston
phone,617 341 6100
state,MA
country,United States
companyOfficers,[]
website,https://www.vrtx.com
maxAge,1
address1,50 Northern Avenue
industry,Biotechnology
ebitdaMargins,0.38861
profitMargins,0.30523002
grossMargins,0.48338002
operatingCashflow,2140039040
revenueGrowth,0.29
operatingMargins,0.37162998
ebitda,2770692096
targetLowPrice,175
recommendationKey,buy
grossProfits,3639846000
freeCashflow,1262742784
targetMedianPrice,265
currentPrice,253.95
earningsGrowth,0.296
currentRatio,4.625
returnOnAssets,0.13846
numberOfAnalystOpinions,25
targetMeanPrice,257.41
debtToEquity,9.2
returnOnEquity,0.24639
targetHighPrice,341
totalCash,6960885248
totalDebt,876800000
totalRevenue,7129658880
totalCashPerShare,27.378
financialCurrency,USD
revenuePerShare,27.564
quickRatio,4.211
recommendationMean,2.1
exchange,NMS
shortName,Vertex Pharmaceuticals Incorpor
longName,Vertex Pharmaceuticals Incorporated
exchangeTimezoneName,America/New_York
exchangeTimezoneShortName,EDT
isEsgPopulated,True
gmtOffSetMilliseconds,-14400000
underlyingSymbol,
quoteType,EQUITY
symbol,VRTX
underlyingExchangeSymbol,
headSymbol,
messageBoardId,finmb_36235
uuid,625901ce-605e-369e-9a46-a48cf891450f
market,us_market
annualHoldingsTurnover,
enterpriseToRevenue,7.058
beta3Year,
enterpriseToEbitda,18.163
52WeekChange,
morningStarRiskRating,
forwardEps,13.4
revenueQuarterlyGrowth,
sharesOutstanding,254252000
fundInceptionDate,
annualReportExpenseRatio,
totalAssets,
bookValue,37.199
sharesShort,3209478
sharesPercentSharesOut,0.0126
fundFamily,
lastFiscalYearEnd,1609372800
heldPercentInstitutions,0.93189
netIncomeToCommon,2176179968
trailingEps,8.338
lastDividendValue,
SandP52WeekChange,
priceToBook,6.826796
heldPercentInsiders,0.00164
nextFiscalYearEnd,1672444800
yield,
mostRecentQuarter,1632960000
shortRatio,1.45
sharesShortPreviousMonthDate,1636934400
floatShares,253674786
beta,0.595324
enterpriseValue,50324250624
priceHint,2
threeYearAverageReturn,
lastSplitDate,967075200
lastSplitFactor,2:1
legalType,
morningStarOverallRating,
earningsQuarterlyGrowth,0.276
priceToSalesTrailing12Months,9.056155
dateShortInterest,1639526400
pegRatio,1.71
ytdReturn,
forwardPE,18.951492
lastCapGain,
shortPercentOfFloat,0.0126
sharesShortPriorMonth,2899452
category,
fiveYearAverageReturn,
previousClose,251.7
regularMarketOpen,252
twoHundredDayAverage,206.86835
trailingAnnualDividendYield,
payoutRatio,0
volume24Hr,
regularMarketDayHigh,254.15
navPrice,
averageDailyVolume10Day,1446460
regularMarketPreviousClose,251.7
fiftyDayAverage,238.534
trailingAnnualDividendRate,
open,252
averageVolume10days,1446460
expireDate,
algorithm,
dividendRate,
exDividendDate,
circulatingSupply,
startDate,
regularMarketDayLow,250.4947
currency,USD
trailingPE,30.456944
regularMarketVolume,1226551
lastMarket,
maxSupply,
openInterest,
marketCap,64567296000
volumeAllCurrencies,
strikePrice,
averageVolume,1679486
dayLow,250.4947
ask,254.7
askSize,800
volume,1226551
fiftyTwoWeekHigh,258.25
fromCurrency,
fiveYearAvgDividendYield,
fiftyTwoWeekLow,176.36
bid,249.83
tradeable,False
dividendYield,
bidSize,1400
dayHigh,254.15
regularMarketPrice,253.95
preMarketPrice,
logo_url,https://logo.clearbit.com/vrtx.com
